GlaxoSmithKline PLC (NYSE:GSK)‘s stock had its “neutral” rating restated by analysts at JPMorgan Chase & Co. in a research note issued on Thursday.

A number of other research firms have also commented on GSK. Beaufort Securities reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Tuesday, August 2nd. Shore Capital reaffirmed a “hold” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, July 27th. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 28th. BNP Paribas reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Sunday, July 31st. Finally, Citigroup Inc. reaffirmed a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, August 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $47.53.

Shares of GlaxoSmithKline PLC (NYSE:GSK) opened at 43.21 on Thursday. GlaxoSmithKline PLC has a 52 week low of $37.24 and a 52 week high of $45.58. The firm has a 50-day moving average of $43.84 and a 200 day moving average of $42.60. The firm has a market capitalization of $105.02 billion, a price-to-earnings ratio of 2700.62 and a beta of 0.85.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/jpmorgan-chase-co-reiterates-neutral-rating-for-glaxosmithkline-plc-gsk-2.html

The company also recently announced a dividend, which will be paid on Thursday, October 13th. Stockholders of record on Friday, August 12th will be issued a $0.494 dividend. The ex-dividend date of this dividend is Wednesday, August 10th. GlaxoSmithKline PLC’s dividend payout ratio is currently 6,600.00%.

Several hedge funds have recently made changes to their positions in the stock. Cypress Wealth Advisors LLC increased its stake in GlaxoSmithKline PLC by 0.6% in the second quarter. Cypress Wealth Advisors LLC now owns 7,977 shares of the pharmaceutical company’s stock worth $346,000 after buying an additional 50 shares during the period. Roffman Miller Associates Inc. PA increased its stake in GlaxoSmithKline PLC by 0.8% in the second quarter. Roffman Miller Associates Inc. PA now owns 9,013 shares of the pharmaceutical company’s stock worth $391,000 after buying an additional 75 shares during the period. Thrivent Financial for Lutherans increased its stake in GlaxoSmithKline PLC by 3.8% in the second quarter. Thrivent Financial for Lutherans now owns 2,651 shares of the pharmaceutical company’s stock worth $115,000 after buying an additional 96 shares during the period. Juncture Wealth Strategies LLC increased its stake in GlaxoSmithKline PLC by 1.4% in the second quarter. Juncture Wealth Strategies LLC now owns 7,100 shares of the pharmaceutical company’s stock worth $308,000 after buying an additional 100 shares during the period. Finally, Rothschild Investment Corp IL increased its stake in GlaxoSmithKline PLC by 0.3% in the second quarter. Rothschild Investment Corp IL now owns 35,463 shares of the pharmaceutical company’s stock worth $1,537,000 after buying an additional 100 shares during the period. Institutional investors own 8.79% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.